How have IBB shares performed in 2024?

iShares Biotechnology ETF's stock was trading at $135.85 on January 1st, 2024. Since then, IBB shares have decreased by 1.2% and is now trading at $134.25. View the best growth stocks for 2024 here .

How often does iShares Biotechnology ETF pay dividends? What is the dividend yield for iShares Biotechnology ETF?

iShares Biotechnology ETF announced a quarterly dividend on Tuesday, December 19th. Stockholders of record on Thursday, December 21st will be paid a dividend of $0.124 per share on Wednesday, December 27th. This represents a $0.50 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Wednesday, December 20th. Read our dividend analysis for IBB .

What does IBB invest in?

iShares Biotechnology ETF is a equity fund issued by iShares. IBB focuses on health care investments and follows the ICE Biotechnology Index (TR) (USD). The fund's investments total to approximately $7.42 billion assets under management.

What stocks does iShares Biotechnology ETF hold?

IBB invests in 231 holdings. Some of the stocks in their portfolio include Amgen (AMGN) , Vertex Pharmaceuticals (VRTX) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) , IQVIA (IQV) , Biogen (BIIB) , Seagen (SGEN) , Moderna (MRNA) , Illumina (ILMN) and Mettler-Toledo International (MTD) .

What is the management fee for iShares Biotechnology ETF?

iShares Biotechnology ETF's management fee is 0.44% and has no other recorded expenses or fee waivers. The net expense ratio for IBB is 0.44%.

When did iShares Biotechnology ETF's stock split?

iShares Biotechnology ETF's stock split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What other stocks do shareholders of iShares Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Biotechnology ETF investors own include NVIDIA (NVDA) , Walt Disney (DIS) , Netflix (NFLX) , Alibaba Group (BABA) , Tesla (TSLA) , Cisco Systems (CSCO) , Micron Technology (MU) , Bank of America (BAC) , Johnson & Johnson (JNJ) and PayPal (PYPL) .

Who are iShares Biotechnology ETF's major shareholders?

iShares Biotechnology ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include International Assets Investment Management LLC (1.01%), Bank Julius Baer & Co. Ltd Zurich (0.53%), Bronte Capital Management Pty Ltd. (0.51%), Commonwealth Equity Services LLC (0.35%), Raymond James & Associates (0.31%) and Raymond James Financial Services Advisors Inc. (0.27%).

How do I buy shares of iShares Biotechnology ETF?

Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IBB

iShares Biotechnology ETF (IBB) Price, Holdings, & News

$134.25

+0.53 (+0.40%)

(As of 02/8/2024 ET)

Compare

Today's Range: $133.15
▼
$134.55
50-Day Range: $122.60
▼
$139.39
52-Week Range: $111.83
▼
$139.49

Volume: 1.25 million shs
Average Volume: 1.87 million shs
Market Capitalization: $7.40 billion

Assets Under Management: $7.42 billion
Dividend Yield: 0.26%
Net Expense Ratio: 0.44%

Get iShares Biotechnology ETF alerts:

About iShares Biotechnology ETF (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

IBB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IBB ETF News Headlines

February 6, 2024 | americanbankingnews.com

iShares Biotechnology ETF Sees Unusually Large Options Volume (NASDAQ:IBB)

January 29, 2024 | benzinga.com

AI, Biotech, Energy Sectors Expect M&A Revival For 2024

February 8, 2024 | The Oxford Club (Ad)

The perfect AI stock under $10

Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.

January 24, 2024 | finance.yahoo.com

Daily Spotlight: Biotech Sector Catches Fire

January 4, 2024 | msn.com

Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024

December 31, 2023 | finance.yahoo.com

IBB Dec 2023 129.000 put

December 29, 2023 | msn.com

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback

December 26, 2023 | msn.com

Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down

February 8, 2024 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

December 20, 2023 | markets.businessinsider.com

Wall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?

See More Headlines

Receive IBB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: iShares
Fund Name: iShares Biotechnology ETF
Tax Classification: Regulated Investment Company
Stock Exchange: NASDAQ
Current Symbol: NASDAQ:IBB
Inception Date: 2/5/2001
Fund Manager: Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Web: N/A
Phone: N/A

Fund Focus

Asset Class: Equity
Benchmark: ICE Biotechnology Index (TR) (USD)
Category: Sector
Focus: Health Care
Development Level: Developed Markets
Region: North America
Number of Holdings: 231

Fund Statistics

Assets Under Management: $7.42 billion
Average Daily Volume: $1.79 million
Discount/Premium: -0.02%

Administrator, Advisor and Custodian

Administrator: JPMorgan Chase Bank, N.A.
Advisor: BlackRock Fund Advisors
Custodian: JPMorgan Chase Bank, N.A.
Distributor: BlackRock Investments, LLC
Transfer Agent: JPMorgan Chase Bank, N.A.
Trustee: N/A
Lead Market Maker: Latour Trading

Options

Optionable: Optionable
Options Volume: 10,259
Put Options: 9,035
Call Options: 1,224
Short Interest: 8,740,000 shs

Miscellaneous

Outstanding Shares: 55,100,000
Beta: 0.73
Creation Unit: 50,000
Creation Fee: $614.00

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

iShares Biotechnology ETF Expenses

Type	IBB	Health Care ETFs	Equity ETFs	NASDAQ ETFs	All ETFs
Management Fee	0.44%	0.57%	0.54%	0.47%	0.51%
Other Expenses	0.00%	0.40%	0.54%	0.33%	0.58%
Total Expense	0.44%	0.72%	0.70%	0.56%	0.70%
Fee Waiver	0.00%	-0.53%	-0.55%	-0.20%	-0.57%
Net Expense	0.44%	0.61%	0.60%	0.53%	0.58%

iShares Biotechnology ETF (IBB) Holdings & Exposure

Top 10 IBB Holdings

IBB Sector Exposure

IBB Industry Exposure

Full Holdings Details

Key Executives

George G. C. Parker Ph.D.
Independent Chairman of the Board of Trustees
Michael Arthur Latham
President, Trustee
Jack Gee
Chief Financial Officer, Treasurer
Geoffrey D. Flynn
Chief Operating Officer, Executive Vice President
Bio & Compensation -
Amy Schioldager
Executive Vice President
Ira P. Shapiro
Vice President, Chief Legal Officer
Matt Tucker
Vice President
Bio & Compensation -
Eilleen M. Clavere
Secretary
Cecilia H. Herbert
Independent Trustee
Charles A. Hurty
Independent Trustee

Similar ETFs

Institutional Ownership

View All Institutional Transactions

IBB ETF - Frequently Asked Questions

How have IBB shares performed in 2024?: iShares Biotechnology ETF's stock was trading at $135.85 on January 1st, 2024. Since then, IBB shares have decreased by 1.2% and is now trading at $134.25.
View the best growth stocks for 2024 here.
How often does iShares Biotechnology ETF pay dividends? What is the dividend yield for iShares Biotechnology ETF?: iShares Biotechnology ETF announced a quarterly dividend on Tuesday, December 19th. Stockholders of record on Thursday, December 21st will be paid a dividend of $0.124 per share on Wednesday, December 27th. This represents a $0.50 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Wednesday, December 20th.
Read our dividend analysis for IBB.
What does IBB invest in?: iShares Biotechnology ETF is a equity fund issued by iShares. IBB focuses on health care investments and follows the ICE Biotechnology Index (TR) (USD). The fund's investments total to approximately $7.42 billion assets under management.
What stocks does iShares Biotechnology ETF hold?: IBB invests in 231 holdings. Some of the stocks in their portfolio include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), IQVIA (IQV), Biogen (BIIB), Seagen (SGEN), Moderna (MRNA), Illumina (ILMN) and Mettler-Toledo International (MTD).
What is the management fee for iShares Biotechnology ETF?: iShares Biotechnology ETF's management fee is 0.44% and has no other recorded expenses or fee waivers. The net expense ratio for IBB is 0.44%.

When did iShares Biotechnology ETF's stock split?: iShares Biotechnology ETF's stock split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.
What other stocks do shareholders of iShares Biotechnology ETF own?: Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Biotechnology ETF investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL).
Who are iShares Biotechnology ETF's major shareholders?: iShares Biotechnology ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include International Assets Investment Management LLC (1.01%), Bank Julius Baer & Co. Ltd Zurich (0.53%), Bronte Capital Management Pty Ltd. (0.51%), Commonwealth Equity Services LLC (0.35%), Raymond James & Associates (0.31%) and Raymond James Financial Services Advisors Inc. (0.27%).
How do I buy shares of iShares Biotechnology ETF?: Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IBB) was last updated on 2/8/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial